<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Clinical</title>
	<atom:link href="http://www.tapanray.in/tag/clinical/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Combating Covid Pandemic: When ‘Something Is Better Than Nothing’</title>
		<link>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=combating-covid-pandemic-when-something-is-better-than-nothing</link>
		<comments>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/#comments</comments>
		<pubDate>Mon, 30 Nov 2020 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['something is better than nothing']]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[dosing]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[nothing]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Phase III]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[side-effects]]></category>
		<category><![CDATA[something]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[useless]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10346</guid>
		<description><![CDATA[As the new Coronavirus overwhelms the world, since its global outbreak, up until November 29, 2020, over 1,458,305 people have died from this pandemic. Understandably, the Governments in all countries are frantically searching for some robust remedial measures to prevent these unfortunate deaths, besides protecting &#8230; <a href="http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/combating-covid-pandemic-when-something-is-better-than-nothing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Greater Patient–Value To Excel With Repurposed Covid Brands</title>
		<link>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-greater-patient-value-to-excel-with-repurposed-covid-brands</link>
		<comments>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/#comments</comments>
		<pubDate>Mon, 23 Nov 2020 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antivirals]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[segments]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10335</guid>
		<description><![CDATA[Regular introduction of new molecules, line extensions or a Novel Drug delivery System (NDDS) has remained the life blood for pharma to rejuvenate a company’s product portfolio for driving organizational growth. But, Covid’s unprecedented and devastating assault on human lives &#8230; <a href="http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Dual Challenge &#8211; To Save Lives And Livelihood</title>
		<link>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-dual-challenge-to-save-lives-and-livelihood</link>
		<comments>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/#comments</comments>
		<pubDate>Mon, 29 Jun 2020 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[comparative]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[dexamethasone]]></category>
		<category><![CDATA[dual]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[favipiravir]]></category>
		<category><![CDATA[herd]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[vaccine-induced]]></category>
		<category><![CDATA[Vulnerable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10146</guid>
		<description><![CDATA[“Jaan hai to jahan hai” (If you have life, you have the world). Prime Minister Modi - with a skillful tweak, used the couplet of the 18th century poet - Mir Taqi Mir, while announcing the criticality of 21-day national lockdown from March 24, 2020 due &#8230; <a href="http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blockchain: Pharma Keeps An Eye On The Ball</title>
		<link>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=blockchain-pharma-keeps-an-eye-on-the-ball</link>
		<comments>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/#comments</comments>
		<pubDate>Sun, 21 Jan 2018 23:31:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bitcoin]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trace]]></category>
		<category><![CDATA[Track]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8772</guid>
		<description><![CDATA[On April 24, 2017, The Wall Street Journal (WSJ) came out with an interesting headline, “Dubai Aims to Be a City Built on Blockchain.” Some may have taken note of it seriously. However, a vast majority of its readers possibly &#8230; <a href="http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/blockchain-pharma-keeps-an-eye-on-the-ball/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical Trials: Critical Need To Improve Patient Participation With Informed Consent</title>
		<link>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent</link>
		<comments>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/#comments</comments>
		<pubDate>Mon, 18 Apr 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[II]]></category>
		<category><![CDATA[III]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed]]></category>
		<category><![CDATA[IV]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[naive]]></category>
		<category><![CDATA[participation]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[phase I]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7600</guid>
		<description><![CDATA[On April 13, 2016, an article in the Wall Street Journal (WSJ) titled, “Clinical Trials Need More Subjects” underscored an important point that the rate at which the clinical researchers are able to recruit and retain patients for ‘Clinical Trials &#8230; <a href="http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: A Major Regulatory Step That Was Long Overdue</title>
		<link>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-a-major-regulatory-step-that-was-long-overdue</link>
		<comments>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/#comments</comments>
		<pubDate>Mon, 21 Dec 2015 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Food Safety & Standards Act]]></category>
		<category><![CDATA[gazette]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[pharmacodynamics]]></category>
		<category><![CDATA[pharmacokinetics]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[RNCOS]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7346</guid>
		<description><![CDATA[Currently in India the nutraceutical products segment, with surrogate or off-label therapeutic claims, is growing at a reasonable pace. Many such products are now being directly promoted to the medical profession, just like any other modern medicines, with therapeutic claims &#8230; <a href="http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
